Titre : Gauging Clinical, Cost Impact of All-Oral DAAs on Hepatitis C
link : Gauging Clinical, Cost Impact of All-Oral DAAs on Hepatitis C
Gauging Clinical, Cost Impact of All-Oral DAAs on Hepatitis C
Gauging Clinical, Cost Impact of All-Oral DAAs on Hepatitis CNOVEMBER 01, 2018
Kenneth Bender, PharmD, MA
A new analysis gauges the impact of all-oral direct-acting antivirals (DAAs) on the clinical and economic outcomes of hepatitis C virus (HCV) in the 4 years since the first of these treatments was approved for marketing in the US.
Haesuk Park, PhD, Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL and colleagues determined that, in this short term, all-oral DAA treatment of HCV was associated with a decreased risk of developing hepatocellular carcinoma (HCC) and decompensated cirrhosis (DCC) and a reduction in healthcare costs.Read the article: https://www.mdmag.com/medical-news/gauging-clinical-cost-impact-of-alloral-daas-on-hepatitis-c
In the journal Hepatology
Hepatology. 2018 Oct 5. doi: 10.1002/hep.30303. [Epub ahead of print]
Anti-virals cure up to 98% of hepatitis C patients since 2014
Oct 8, 2018Paul Cullen
Use of revolutionary drugs has led to ‘a triumph of science’, says hepatologist
Up to 98 per cent of patients with hepatitis C virus have been cured thanks to the use of revolutionary anti-viral drugs over the past four years, new figures show.
The figures from the national treatment registry for Irish hepatitis C patients represent “a triumph of science”, Dr Diarmuid Houlihan, a hepatologist at St Vincent’s University Hospital told a conference in Dublin on Monday.
Hepatitis C is a virus that infects and damages the liver. It can cause inflammation scarring of the liver, which in some people can progress to cause serious liver damage, such as cirrhosis. It is often referred to as a silent disease, as symptoms can take several years to develop and people do not realize they have the disease.
On This Blog
Link to a collection of current research articles regarding the effectiveness and safety of generic hepatitis C medicines. Read news articles addressing the high cost, insurance restrictions; private insurers/Medicaid and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"
Thus articles Gauging Clinical, Cost Impact of All-Oral DAAs on Hepatitis C
that is all articles Gauging Clinical, Cost Impact of All-Oral DAAs on Hepatitis C This time, hopefully can provide benefits to you all. Okay, see you in another article post.
You are now reading the article Gauging Clinical, Cost Impact of All-Oral DAAs on Hepatitis C the link address https://newsaninpiration.blogspot.com/2018/11/gauging-clinical-cost-impact-of-all.html
0 Response to "Gauging Clinical, Cost Impact of All-Oral DAAs on Hepatitis C"
Post a Comment